NYXH ▲ +7.3% - Nyxoah SA $NYXH - Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients Nyxoah shares rose 7.3% after the company announced that its ACCCESS U.S. pivotal study met both primary safety and efficacy endpoints in patients with complete concentric collapse, a specific form of obstructive sleep apnea. The positive trial results validate the company's treatment approach and bring it closer to potential regulatory approval for this patient population. 02-SEP-2026 04:05 PM ET